Market Access Views & Analysis

Views & Analysis

Market Access

Progress with the UK’s VPAG

Leela Barham looks at the first operational review meeting minutes that have been published on the VPAG, the UK’s latest scheme on branded medicines pricing and access, building on previous

Market Access

Updating of England’s budget impact test threshold

England has a lot of ways to put downward pressure on prices of new treatments and the budget impact test - prompting commercial discussions if a new treatment looks like it will cost more

Market Access

Medical start-ups must address the evolving risks of the FDA...

Embarking on the journey of a medical start-up is like navigating a complex labyrinth, where the final prize is the coveted FDA approval.

Market Access

Inflation Reduction Act proves positive boost for biosimilar...

For the pharma industry, the IRA has made headlines due to it allowing price negotiations on top-selling treatments.

Market Access

Part 1: Accelerating the medical, legal and regulatory (MLR)...

Medical, legal and regulatory review (MLR review) of promotional as well as non-promotional materials is one of the core responsibilities of medical and commercial teams within any life sci

Market Access